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ABSTRACT  27 
Objectives 28 
Patients receiving glucocorticoid treatment are prone to develop metabolic complications. In 29 
preclinical studies metformin prevented the development of the metabolic syndrome during 30 
glucocorticoid excess. We herein investigated the metabolic effect of metformin during 31 
glucocorticoid treatment in non-diabetic patients. 32 
Methods 33 
In a double-blind, placebo-controlled trial, patients starting glucocorticoid treatment 34 
(prednisone, prednisolone or methylprednisolone) for four weeks were randomized to 35 
concomitantly receive metformin (850mg once daily for one week followed by 850mg twice 36 
daily for three weeks) or placebo. All patients underwent a standardized oral glucose 37 
tolerance test at baseline and after four weeks. The primary endpoint was change in the 2h 38 
area under the curve (AUC) of glucose during the oral glucose tolerance test between baseline 39 
and four weeks.  40 
Results 41 
29 of 34 randomized non-diabetic patients completed the trial (17 metformin, 12 placebo). In 42 
patients allocated to placebo, median glucose 2h AUC increased from baseline to four weeks 43 
(836 [IQR 770-966] to 1202 [1009-1271] mmol l
-1
 min
-1
; p=0.01). In contrast, glucose levels 44 
remained similar to baseline in the metformin group (936 [869-1003] to 912 [825-1011]  45 
mmol l
-1
 min
-1
; p=0.83). This change within four weeks was different between both groups 46 
(p=0.005). Glucocorticoid equivalent doses were similar in both groups (placebo: 980.0 47 
[560.0-3259.8]mg/28d; metformin: 683.0 [437.5-1970.5]mg/28d; p=0.26). 48 
Conclusions  49 
In this first randomized, controlled trial of metformin targeting metabolic complications in 50 
patients needing glucocorticoid therapy, we observed a beneficial effect of metformin on 51 
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glycaemic control. Metformin thus seems to be a promising drug for preventing metabolic 52 
side effects during systemic glucocorticoid treatment.53 
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 INTRODUCTION 54 
 55 
Up to 2.5% of the adult western population receive systemic glucocorticoid therapy, mostly 56 
for inflammatory conditions. Diabetes mellitus, dyslipidaemia, central obesity and 57 
hypertension are well-known and common side effects of glucocorticoid treatment 
1, 2
.  58 
Especially, diabetes mellitus is a recurring problem with a reported prevalence of up to 40% 59 
in patients receiving long-term glucocorticoid treatment 
3-7
. Even if used as an antiemetic drug 60 
in cancer patients, glucocorticoids clearly increased the risk of diabetes mellitus 
7
. In contrast 61 
to other well-known side effects of glucocorticoids, such as gastric ulcer disease, no 62 
randomized-controlled evidence exists that has investigated potential therapeutics for the 63 
treatment of metabolic side effects of glucocorticoids. 64 
 65 
Many of the changes seen in glucocorticoid excess, such as gluconeogenesis,  correspond to 66 
metabolic steps regulated by adenosine-monophosphate-activated protein kinase (AMPK) 
8
. 67 
AMPK is a key regulator of energy metabolism and mediator of several hormones affecting 68 
appetite and metabolism 
9
. Metformin, a widely used drug for prevention and treatment of 69 
diabetes mellitus type 2, exerts most of its beneficial effects on metabolism through the 70 
activation of AMPK 
10, 11
. We have shown previously that glucocorticoid treatment changes 71 
AMPK activity in human adipocytes in vitro and reduced AMPK activity is seen in adipose 72 
tissue of patients with Cushing’s syndrome 
12, 13
. Importantly, metformin reversed the effects 73 
of corticosteroids on AMPK in vitro both in primary hypothalamic cell culture as well as in 74 
adipocytes, suggesting that metformin and glucocorticoids influence the AMPK signalling 75 
pathway in opposite ways and that the metformin effect is able to override the cortisol effect 76 
12, 14
. In vivo studies showed that treatment with an AMPK activator prevented glucocorticoid-77 
induced increase in glucose levels, hepatic glycogen production and hepatic steatosis in rats 78 
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15
. Furthermore, metformin efficiently prevented the dexamethasone-induced deterioration of 79 
glucose metabolism in mice and horses 
16, 17
. These data suggest that metformin treatment 80 
could be beneficial in preventing metabolic complications in patients receiving long-term 81 
corticosteroid treatment.  82 
 83 
In the first double-blind, randomized, placebo-controlled trial we investigated the metabolic 84 
effects of metformin during glucocorticoid treatment in non-diabetic patients starting 85 
treatment with corticosteroids for at least 4 weeks. 86 
 87 
 88 
MATERIALS AND METHODS  89 
 90 
Study Design 91 
In this randomized, placebo-controlled, double-blind study, we included patients starting 92 
glucocorticoid treatment for at least 4 weeks. Participants were recruited at several 93 
departments at the University Hospital Basel and the Cantonal Hospital Aarau from August 94 
2010 to March 2015. Patients were randomized in a 1:1 ratio to receive either metformin 95 
850mg daily p.o. for one week followed by 850mg twice daily p.o. for another three weeks or 96 
identical placebo (Merck). The study was terminated after four weeks in all patients, also in 97 
cases where glucocorticoid treatment was continued. The study was registered at 98 
Clinicaltrials.gov NCT01187849. 99 
 100 
Patients 101 
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Inclusion criterion was a newly initiated treatment with prednisone ≥7.5mg or an equivalent 102 
glucocorticoid for at least 4 weeks. Glucocorticoid tapering was determined by the treating 103 
physicians.  Exclusion criteria were preexisting diabetes mellitus (according to the American 104 
Diabetes Association criteria); renal insufficiency (estimated glomerular filtration rate using 105 
the CKD-EPI formula above 60 ml/min/1.73); severe conditions affecting renal function (e.g. 106 
dehydration, fever, severe infection); severe conditions causing tissue hypoxia (e.g. acute 107 
cardiac or respiratory insufficiency); scheduled examination using intravascular contrast agent 108 
containing iodine; alcohol consumption of more than 40g/d (male) or 20g/d (female); known 109 
allergy to metformin;  pregnancy or breast feeding; any condition compromising the ability of 110 
the subject to give written informed consent. 111 
The study was approved by the ethical committees of the participating hospitals and 112 
Swissmedic and was conducted in accordance with the ethical guidelines of the Declaration of 113 
Helsinki. Written informed consent was obtained from all participating subjects before 114 
randomization. 115 
 116 
Study Assessment 117 
At baseline and after four weeks, a standardized 2-hour 75g oral glucose tolerance test was 118 
performed. After an overnight fast baseline blood samples for fasting glucose, insulin, 119 
HbA1c, a full lipid profile and safety blood measurements were taken directly before 120 
ingestion of glucose. Additional blood samples for glucose were taken 30, 60, 90, and 120 121 
minutes thereafter.. Physical examination, urine analysis were performed and doses of 122 
glucocorticoids were assessed at both visits. After one week, a telephone call took place to 123 
assess compliance, adverse events and dosage of glucocorticoids. Three forms of 124 
glucocorticoids were prescribed: prednisone, prednisolone and methylprednisolone (Suppl. 125 
Tab. 1). If needed, doses of glucocorticoids, e.g. methylprednisolone, were converted to 126 
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equivalent doses of prednisone 
18
. Due to glucocorticoid tapering, cumulative glucocorticoid 127 
doses were calculated as follows: area under the curve was calculated using glucocorticoid 128 
doses at baseline, one and four weeks. The average daily prednisone dose was calculated as 129 
the area under the curve of the 28 study days.   130 
Plasma glucose and lipids were measured with enzymatic assays (Cobas® modular analyser, 131 
Roche Diagnostics, USA). Serum insulin and c-peptide were assessed using immune assays 132 
(Immulite® 2000, Siemens, Germany). Hba1c was analysed in EDTA plasma with high 133 
performance liquid chromatography (G8 HPLC Analyzer, Tosho Bioscience, USA). 134 
Measurements of all blood parameters were performed in the routine central laboratory unit of 135 
the University Hospital Basel. The reported HOMA index was calculated according to 136 
Matthews et al. 
19
. Body impedance analysis (Bodyimpedance Analyzer Model BIA 101, 137 
Akern Srl Florence Italy) was performed to assess body composition and energy expenditure.  138 
A randomization list based on single sequence of random assignments, was created by the 139 
Pharmaceutical Unit of the University Hospital Basel. Patients as well as study personnel 140 
were blinded to the medication allocation.  141 
  142 
Study End Points 143 
The predefined primary endpoint was the change in the area under the concentration-time 144 
curve (AUC) for glucose during the 75g oral glucose tolerance test between baseline and four 145 
weeks. Predefined secondary endpoints included change in fasting glucose levels, glycated 146 
haemoglobin levels (HbA1c), Homeostatis Model Assessment (HOMA)-Index, fasting lipid 147 
levels, body mass index, body composition and waist/hip ratio.  148 
 149 
Statistical Analysis 150 
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According to the protocol, the primary analysis followed the intention to treat principle, i.e. 151 
patients with complete follow-up were analysed in the groups to which they were randomized. 152 
Patients in the metformin group were expected to have unchanged 2 hour glucose levels after 153 
ingestion of 75g glucose, while patients in the placebo group would have an increase of 154 
approximately 25%. Based on these assumptions, a sample size of 66 patients (33 per arm) 155 
was calculated to detect a significant difference between these distributions with a power of 156 
90% at the two-sided 5% level. Discrete variables are expressed as counts (percentages) and 157 
continuous variables as median (interquartile range, IQR). To compare changes across 158 
treatment groups the Mann-Whitney-U test was used for continuous data and the Fisher’s 159 
exact test for categorical data. The Wilcoxon signed-rank test was used for comparisons 160 
within subjects. Incremental AUC for glucose values (during 120 minutes of a standardized 161 
oral glucose tolerance test) and glucocorticoid doses (during 28 days of study duration) was 162 
calculated using the trapezoid rule. To adjust for relevant covariates linear regression analyses 163 
were employed. P value <0.05 was defined as significant. Data were analysed using statistical 164 
software (Statistical Package for Social Sciences, IBM SPSS Version 22, Chicago IL). 165 
Figures were drawn using GraphPad Prism (GraphPad Software Inc., LaJolla, CA). 166 
 167 
 168 
RESULTS 169 
 170 
Baseline characteristics 171 
34 individuals were randomly assigned (1:1) to receive metformin (n=20) or placebo (n=14). 172 
In the metformin group two patients withdrew from the study due to gastrointestinal 173 
symptoms and vertigo, respectively; another patient was lost to follow up after the baseline 174 
visit. In the placebo group one patient did not receive glucocorticoids as foreseen and one 175 
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patient was lost to follow up. A total of 17 subjects in the metformin group and 12 subjects in 176 
the placebo group completed the trial (Fig. 1).  Patients in both treatment groups were well 177 
matched for baseline characteristics (Tab. 1). Baseline glucocorticoid doses were similar in 178 
both groups (metformin: 35.0 (11.3-50.0) mg/d; placebo:  30.0 (20.0-362.5) mg/d; p=0.48). A 179 
comparison between patients completing the trial (n=29) and patients dropping out (n=5) 180 
showed no difference in baseline criteria except for glucocorticoid doses (complete: 40.0 181 
(20.0-95.0) mg/d; drop out:  12.5 (10.0-26.3) mg/d, p=0.03) (Suppl. Tab. 2).  AUC prednisone 182 
doses in patients completing the trial remained similar in both groups throughout the study 183 
(metformin: 683.0 (437.5-1970.5) mg/28d; placebo: 980.0 (560.0-3259.8) mg/28d, p=0.26).  184 
Indications for glucocorticoid treatment are presented in Tab. 2.  Concomitant medication 185 
with potential effect on glucose and/ or lipid metabolism is listed in Supplemental Table 3. 186 
Due to slow study recruitment and time expiry of study drug the study had to be prematurely 187 
terminated. This led to fewer study participants than intended and to an unbalanced 188 
randomization. 189 
 190 
 191 
Effect of Metformin on Glycaemia 192 
 2h-AUC glucose remained similar from baseline to four weeks in the metformin group 193 
(p=0.83), while increasing in the placebo group (p=0.01; Fig. 2A-C). Accordingly, the 194 
primary endpoint of 2h-AUC glucose change within four weeks was different between both 195 
groups (p=0.005; Tab 3; Fig. 2D). After adjustment for gender, cumulative glucocorticoid 196 
dose and HbA1c, treatment group remained strongly associated with 2h-AUC glucose 197 
(adjustment for gender: treatment group p=0.006, R
2
=0.32; adjustment for glucocorticoid 198 
dose: treatment group p=0.003, R
2
=0.33; adjustment for HbA1c: treatment group p=0.002, 199 
R
2
=0.38). Among the secondary endpoints, the change in fasting glucose, fasting insulin and 200 
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HOMA-index were different between the two groups (p=0.01, p=0.003, and p=0.035, 201 
respectively; Fig. 3A-F). We observed no change in HbA1c in the treatment and placebo 202 
groups during the study period (p=0.64; Fig. 3G-H).   203 
Furthermore, we aimed to differentiate between responders and non-responders to metformin. 204 
As the 2h AUC glucose increase in the placebo group was 40.3 (18.9-51.0)%, we allocated 205 
patients in the metformin group with an increase below 20% to responders, and patients with 206 
an increase equal and above 20% to non responders.  This resulted in three patients, which 207 
were classified as non-responders. Their baseline characteristics are listed in Supplement 208 
Table 4.  209 
Effect of Metformin on Lipids 210 
Fasting triglyceride levels did not change during the trial and there was no difference between 211 
groups (p=0.30). Total cholesterol levels increased only in the placebo group (p=0.02) while 212 
remaining stable in the metformin group (p=0.10). No difference in cholesterol between 213 
groups was observed (p=0.15). HDL levels increased in both groups compared to baseline 214 
(metformin: p<0.0001; placebo: p=0.003). The HDL increase over the four weeks was more 215 
pronounced in the metformin group (p=0.04). LDL levels did not change during the trial and 216 
there was no difference between groups (p=0.71; Tab 3). 217 
 218 
Effect of Metformin on Body Composition and Energy Expenditure 219 
We identified no change in BMI, waist-hip ratio, basal metabolic rate, fat free mass and fat 220 
mass during the study period; there was no difference across treatment groups (Tab. 3). 221 
 222 
Adverse events  223 
Gastrointestinal symptoms were present in 20.0% of patients in the metformin and in 21.4% 224 
of patients in the placebo group (Suppl. Tab 5). All gastrointestinal symptoms were either 225 
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mild or moderate. There was no difference between groups (p=0.99). In the metformin group 226 
one subject discontinued the study due to gastrointestinal symptoms, another patient 227 
discontinued due to vertigo. One subject in the metformin group was hospitalized for further 228 
evaluation of the underlying disease (vasculitis) after study inclusion. The hospitalization was 229 
rated as serious adverse event unrelated to the study drug.  230 
 231 
 232 
DISCUSSION 233 
 234 
In this trial with non-diabetic patients receiving systemic glucocorticoids, we demonstrate for 235 
the first time that preventive metformin treatment is superior to placebo with respect to 236 
glycaemic control as indicated by 2h glucose AUC, HOMA-Index, fasting glucose and fasting 237 
insulin. This effect was consistent after adjustment for gender, cumulative glucocorticoid dose 238 
and HbA1c. While HDL cholesterol levels increased in both groups during GC treatment, we 239 
did not observe a change in triglycerides, LDL, body weight or body composition. 240 
 241 
Despite the very frequent use of glucocorticoids and the well-known detrimental impact on 242 
glucose metabolism, hardly any randomized-controlled trials have investigated the prevention 243 
of glucocorticoid-induced diabetes 
20-23
. In one of these trials, troglitazone prevented 244 
deterioration of glucose metabolism during glucocorticoid treatment, while pioglitazone and 245 
metformin had no effect 
24
. Noteworthy, troglitazone can no longer be used as it was 246 
withdrawn from the market. Compared to our study, duration of metformin and steroid 247 
treatment was very short and metformin dose was low. Two other randomized controlled 248 
trials targeting the GLP-1 pathway produced heterogenous results 
25, 26
.  Importantly, all three 249 
studies were performed in individuals without inflammatory disease, thus not representing the 250 
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patients in need of glucocorticoid treatment. As inflammation is a known mediator of insulin 251 
resistance, it is important to investigate potential benefits of metformin in an appropriate 252 
study population 
27
. Therefore, more convincing strategies to prevent metabolic side effects of 253 
glucocorticoid treatment in patients indeed suffering from inflammatory diseases are needed.  254 
From a pathophysiological point of view, metformin is an attractive preventive treatment 255 
strategy in patients receiving corticosteroids. Metformin’s mode of function has been 256 
extensively discussed and several mechanisms such as inhibition of glycerolphosphate 257 
dehydrogenase, enhanced action of glucagon-like-peptide 1 or antagonism of glucagon have 258 
been proposed 
28-31
. Overall, activation of AMPK seems to play an important role 
10, 11, 32, 33
. 259 
AMPK is generally considered to be a master regulator of energy metabolism, sensing energy 260 
depletion and activating energy-generating pathways 
9
.  Glucocorticoids have been shown to 261 
inhibit AMPK activity and, importantly, metformin was able to reverse this inhibitory effect 262 
of glucocorticoids on AMPK in vitro and in animal studies 
12, 13, 15
. 263 
In accordance with these experimental data, our study showed that metformin favourably 264 
influences several side effects of glucocorticoid therapy. We found that metformin prevented 265 
an increase of 2h glucose AUC indicating preservation of glucose tolerance. The HOMA-266 
Index, a marker of insulin resistance, clearly improved in the metformin group while 267 
deterioration was observed in the placebo group. Fasting glucose levels decreased in the 268 
metformin group while increasing in the placebo group during the study period. Moreover, 269 
change in fasting insulin was different between groups. Still, we could not identify a 270 
difference in HbA1c. However, our study was conducted over four weeks while HbA1c 271 
reflects average blood glucose over the previous 8 to 12 weeks 
34
. Therefore, we speculate 272 
that a longer study duration could show a beneficial effect on HbA1c.  273 
Compared to glucose metabolism, the role of glucocorticoids in lipid metabolism is more 274 
controversial. Patients with endogenous overproduction of glucocorticoids are prone to 275 
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develop dyslipidaemia 
1
. Similarly, glucocorticoid administration has been associated with 276 
deterioration of lipid metabolism 
35
. Interestingly, in a large observational study, 277 
glucocorticoids were associated with higher HDL levels and glucocorticoid treatment was 278 
shown to normalize HDL levels in rheumatoid arthritis 
36-38
. This positive effect of 279 
glucocorticoids may be due to the reduction of the inflammatory burden rather than a direct 280 
impact on lipid metabolism. 281 
While the role of glucocorticoids on lipids remains unclear, metformin presumably has a 282 
beneficial effect by decreasing triglycerides and LDL cholesterol while increasing HDL 283 
cholesterol independent of glucose metabolism 
39-41
. In our trial, we did not observe a change 284 
in triglycerides nor LDL; however, HDL cholesterol levels increased in both study groups. 285 
This finding may be due to a direct effect of glucocorticoids or rather an indirect effect of 286 
lowering the inflammatory status.  287 
Central obesity is another characteristic feature of chronic high dose glucocorticoid exposure 288 
42, 43
. In the Diabetes Prevention Program Study metformin reduced body weight for around 289 
2kg during a two year study period in diabetic patients 
44
. Thus, metformin exerts opposite 290 
effects to glucocorticoids regarding weight. 291 
In our trial, four weeks of glucocorticoid treatment did not result in change of body 292 
composition or waist/hip ratio in either study groups. Consequently, no effect of metformin 293 
could be observed. Possibly, the study duration was too short and the sample size too small; 294 
longer treatment duration with corticosteroids and metformin or placebo, respectively, may 295 
provide different results.  296 
 297 
Gastrointestinal adverse events occurred in similar number in both treatment groups. Several 298 
other studies found metformin to be safe and well tolerated 
45
. 299 
 300 
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Our study has some limitations. First, the study was prematurely terminated which led to a 301 
rather small sample size. This was due to a combination of slow and difficult recruitment and 302 
time to expiry of the trial drug. Nevertheless, due to higher than expected effect of metformin 303 
the sample size was sufficient to demonstrate a significant effect on the primary and several 304 
secondary endpoints. Since we show a highly significant result, lack of statistical power is not 305 
an issue. Second, more and predominantly male patients were in the metformin group. Third, 306 
causes of glucocorticoid administration were very variable and the study design did not allow 307 
stratification of diseases. While overall glucocorticoid doses were not different between 308 
groups, some participants in the placebo group received the highest doses. Importantly, 309 
variability of indications and administration of glucocorticoid treatment mirror real life 310 
practice, and make the results more generalizable. Fourth, baseline HbA1c was slightly higher 311 
in the placebo group, potentially putting these patients at higher risk for development of 312 
diabetes. Importantly, the difference in HbA1c was not significant between groups, and the 313 
primary endpoint remained highly significant after adjustment for HbA1c.  314 
Our results indicate that metformin prevents deterioration of glucose metabolism if treatment 315 
is timed with initiation of glucocorticoids. This study provides the basis for metformin as a 316 
preventive treatment in patients newly receiving glucocorticoid therapy. Further studies are 317 
needed to test if occurrence of glucocorticoid-induced diabetes can be reduced, and if 318 
metformin has similar beneficial effects in patients with continuous glucocorticoid treatment. 319 
As our patient number was too small to identify unique characteristics distinguishing 320 
responders from non-responders, this remains to be investigated in future studies. 321 
In summary, this is the first randomized-controlled trial showing that metformin has a 322 
beneficial preventive effect on glycaemic control in non-diabetic patients receiving systemic 323 
glucocorticoid therapy.  324 
 325 
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FIGURE LEGENDS 497 
 498 
Fig. 1. Enrolment of participants 499 
 500 
Fig. 2. Change in glucose during oral glucose tolerance test 501 
A) Plasma glucose values during oral glucose tolerance test at baseline and after four weeks in 502 
placebo treated patients. B) Glucose values during oral glucose tolerance test at baseline and 503 
after four weeks in patients treated with metformin. C) 2h-AUC glucose in both study groups 504 
at baseline and after 4 weeks. D) Differences in 2h-AUC glucose between baseline and four 505 
weeks in each study group. Data represent median values error bars indicate interquartile 506 
ranges. * indicates p-value <0.05. 507 
 508 
Fig. 3. Change in HOMA-Index, fasting glucose, fasting insulin and HbA1c 509 
 A) HOMA-Index at baseline and after four weeks for both study groups. B) Differences in 510 
HOMA-Index between baseline and four weeks in each study group. C) Fasting glucose at 511 
baseline and after four weeks in each study group. D) Differences in fasting glucose between 512 
baseline and four weeks in each study group. E) Fasting insulin at baseline and after four 513 
weeks in each study group. F) Differences in fasting insulin at baseline and after four weeks 514 
in each study group. G) HbA1c at baseline and after four weeks in each study group. H) 515 
Differences in between baseline and four weeks in each study group. Data represent median 516 
values, error bars indicate interquartile ranges. * indicates p-value <0.05. 517 
 518 
 519 
 520 
 521 
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Tab. 1 Baseline characteristics (including 5 patients with missing outcome variables); median 
values (IQR) 
 Placebo (n=14) Metformin (n=20) P-Value 
Male sex (%) 35.7 70.0 0.08 
Age (years) 56.5 (46.5-67.8) 58.0 (35.8-74.3) 0.69 
BMI (kg/m
2
) 25.7 (20.6-27.5) 24.2 (21.6-28.6) 0.69 
Waist/hip ratio 0.9 (0.8-1.0) 1.0 (0.9-1.0) 0.24 
Systolic blood pressure (mmHg) 129 (120-147) 132 (116-139) 0.96 
Diastolic blood pressure (mmHg) 80 (71-86) 75 (70-80) 0.26 
HbA1c (%) 5.7 (5.4-5.9) 5.4 (5.3-5.8) 0.32 
HbA1c (mmol/mol) 39.0 (36.0-40.0) 36.0 (34.0-40.0) 0.32 
Fasting glucose (mmol/l) 5.0 (4.6-5.3) 4.8 (4.6-5.3) 0.77 
Fasting insulin (mIU/L) 5.8 (2.5-11.1) 8.6 (4.3-14.8) 0.29 
HOMA Index 1.0 (0.5-2.0) 1.9 (1.0-3.4) 0.18 
Glucose 2h AUC (mmol l
-1
 min
-1
) 864.8 (782.6-1012.1) 937.5 (872.3-991.1) 0.34 
Triglycerides (mmol/l) 1.1 (0.9-1.2) 1.3 (0.9-1.7) 0.32 
Total cholesterol (mmol/l) 4.8 (4.4-5.2) 4.8 (4.3-5.6) 0.64 
HDL cholesterol (mmol/l) 1.4 (1.0-1.7) 1.2 (1.0-1.4) 0.48 
LDL cholesterol  
(mmol/l) 
2.9 (2.6-3.1) 3.1 (2.5-3.8) 0.27 
Creatinine (umol/l) 67.0 (60.8-75.5) 79.0 (59.8-87.3) 0.27 
Prednisone dosage  (mg/d) 30.0 (20.0-362.5)  35.0 (11.3-50.0) 0.48  
Basal metabolic rate (kcal) 1665 (1423-1923) 1730 (1593-1823) 0.60 
Fat free mass (kg) 57.0 (47.2-62.9) 57.9 (50.6-63.3) 0.70 
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Fat mass (kg) 16.9 (9.3-22.1) 14.6 (8.5-21.2) 0.77 
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Tab. 2 Indications for glucocorticoid treatment (including 5 patients with missing outcome 
variables 
Diagnosis Placebo (n=14) Metformin (n=20) 
Arthritis 2 2 
Vasculitis 1 3 
Polymyalgia rheumatica 1 2 
Eosinophilic fasciitis 1  
Lupus erythematodes 1  
Sarcoidosis  2 
Sclerosing Lymphadenopathy 1  
Cutaneous sclerosis  1 
MorbusWegener 1  
Alopecia areata  1 
Pemphigus 2 1 
Eczema  1 
Metastatic prostate carcinoma  1 
Astrocytoma 1  
Organizing Pneumonia  1 
Allergic bronchopulmonary 
aspergillosis 
 1 
Myasthenia gravis  1 
Endocrine Orbitopathy 3 2 
Scleritis  1 
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Tab. 3 Primary and secondary endpoints; median values (IQR); for each parameter, change 
from baseline was compared between groups (metformin vs. placebo) using the Mann-
Whitney-U test and within-groups using the Wilcoxon signed-rank test (
a 
Prednisone dosage 
was calculated as area under the curve using glucocorticoid doses at baseline, one and four 
weeks). 
 
 Placebo Metformin Between- 
group p 
Glucose 2h AUC (mmol l
-1
 min
-1
;  
17 patients on metformin vs. 8 on 
placebo)  
   
  Baseline 835.5 (769.9-
966.0) 
936.0 (869.3-
1002.8) 
0.005   4 weeks 1202.3 (1008.8-
1270.9) 
912.0 (825.0-
1011.0) 
  Within-group p 0.01 0.83 
HOMA-Index  
(17 vs. 9) 
  
 
  Baseline 1.0 (0.4-1.4) 2.2 (1.0-3.6) 
0.035   4 weeks 1.5 (0.8-2.0) 1.1 (0.6-2.7) 
  Within-group p 0.07 0.04 
Fasting glucose (mmol/l; 17 vs. 
11) 
  
 
  Baseline 4.8 (4.4-5.3) 4.8 (4.6-5.3) 0.01 
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  4 weeks 5.3 (4.5-5.6) 4.6 (4.2-5.0) 
  Within-group p 0.07 0.04 
Insulin (mIU/L; 17 vs. 10)    
Baseline 5.4 (2.3-8.3) 9.3 (4.5-15.6) 
0.003 4 weeks 6.8 (4.0-13.4) 5.7 (3.3-13.4) 
Within-group p 0.07 0.06 
HbA1c 
(%; 16 vs.12) 
  
 
  Baseline 5.7 (5.3-5.9) 5.4 (5.3-6.0) 
0.64   4 weeks 5.8 (5.3-5.9) 5.5 (5.3-6.0) 
  Within-group p 0.19 0.48 
HbA1c 
(mmol/mol; 16 vs. 12) 
  
 
  Baseline 39.0 (34.0-41.0) 36.0 (34.0-42.0) 
0.64   4 weeks 40.0 (34.0-41.0) 37.0 (34.0-42.0) 
  Within-group p 0.19 0.48 
Triglycerides (mmol/l; 17 vs. 11)    
  Baseline 1.1 (0.8-1.1) 1.3 (0.9-1.6) 
0.30   4 weeks 1.2 (0.9-1.3) 1.2 (1.0-1.4) 
  Within-group p 0.17 0.65 
Total cholesterol (mmol/l; 17 vs. 
11) 
  
 
  Baseline 4.8 (4.5-5.1) 4.8 (4.2-5.7) 
0.15 
  4 weeks 5.6 (4.8-6.9) 5.4 (4.6-6.4) 
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  Within-group p 0.02 0.10 
HDL  
(mmol/l; 17 vs. 11) 
  
 
  Baseline 1.5 (1.0-1.6) 1.3 (1.1-1.5) 
0.04   4 weeks 2.0 (1.7-2.8) 1.7 (1.3-1.9) 
  Within-group p 0.003 <0.0001 
LDL 
(mmol/l; 17 vs. 11) 
  
 
Baseline 2.9 (2.6-3.1) 3.0 (2.3-3.9) 
0.71 4 weeks 3.0 (2.7-3.4) 3.0 (2.5-3.8) 
Within-group p 0.53 0.83 
BMI  
(kg/m
2
; 17 vs. 12) 
  
 
  Baseline 25.7 (21.9-26.4) 23.7 (20.9-28.7) 
0.30   4 weeks 25.5 (21.4-27.4) 23.6 (21.1-28.7) 
  Within-group p 0.72 0.26 
Waist-hip ratio (16 vs. 9)    
  Baseline 0.9 (0.8-1.0) 1.0 (0.9-1.0) 
0.36   4 weeks 1.0 (0.9-1.0) 1.0 (0.9-1.0) 
  Within-group p 0.17 0.93 
Basal metabolic rate  
(kcal; 14 vs. 10) 
  
 
  Baseline 1665 (1523-1888) 1730 (1550-
1835) 
0.95 
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  4 weeks 1620 (1418-1952) 1745 (1513-
1820) 
  Within-group p 0.65 0.55 
Fat free mass  
(kg; 14 vs. 10) 
  
 
  Baseline 57.0 (47.5-62.3) 58.3 (52.9-63.9) 
0.38   4 weeks 54.7 (41.6-63.2) 57.7 (51.5-64.7) 
  Within-group p 0.37 0.95 
Fat mass  
(kg; 14 vs. 10) 
  
 
  Baseline 16.9 (10.4-21.3) 14.6 (9.8-22.3) 
0.98   4 weeks 19.2 (12.1-22.8) 17.1 (9.5-22.9) 
  Within-group p 0.59 0.35 
AUC Prednisone dosage 
(mg/28d: 17 vs 12)
 a
 
980.0 (560.0-
3259.8) 
683.0 (437.5-
1970.5) 
0.26 
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Fig. 1. Enrolment of participants  
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Fig. 2. Change in glucose during oral glucose tolerance test  
A) Plasma glucose values during oral glucose tolerance test at baseline and after four weeks in placebo 
treated patients. B) Glucose values during oral glucose tolerance test at baseline and after four weeks in 
patients treated with metformin. C) 2h-AUC glucose in both study groups at baseline and after 4 weeks. D) 
Differences in 2h-AUC glucose between baseline and four weeks in each study group. Data represent median 
values error bars indicate interquartile ranges. * indicates p-value <0.05.  
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Fig. 3. Change in HOMA-Index, fasting glucose, fasting insulin and HbA1c  
A) HOMA-Index at baseline and after four weeks for both study groups. B) Differences in HOMA-Index 
between baseline and four weeks in each study group. C) Fasting glucose at baseline and after four weeks in 
each study group. D) Differences in fasting glucose between baseline and four weeks in each study group. 
E) Fasting insulin at baseline and after four weeks in each study group. F) Differences in fasting insulin at 
baseline and after four weeks in each study group. G) HbA1c at baseline and after four weeks in each study 
group. H) Differences in between baseline and four weeks in each study group. Data represent median 
values, error bars indicate interquartile ranges. * indicates p-value <0.05.  
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